Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Protagenic Therapeutics's shares outstanding for the quarter that ended in Dec. 2025 was 1.94 Mil.
Protagenic Therapeutics's quarterly shares outstanding
stayed the same
from Sep. 2025 (1.94 Mil) to Dec. 2025 (1.94 Mil).
Protagenic Therapeutics's annual shares outstanding
increased
from Dec. 2023 (0.32 Mil) to Dec. 2024 (0.52 Mil).
It means Protagenic Therapeuticsissued new shares from Dec. 2023 to Dec. 2024 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Protagenic Therapeutics Shares Outstanding (EOP) Related Terms
Protagenic Therapeutics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Protagenic Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTIX vs CERO, CYTOF, CARM: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Protagenic Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagenic Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Protagenic Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 1.94 Mil mean?
Protagenic Therapeutics (PTIX) has a Shares Outstanding (EOP) of 1.94 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Protagenic Therapeutics and its competitors.
Is Protagenic Therapeutics' Shares Outstanding (EOP) too high?
Protagenic Therapeutics' current Shares Outstanding (EOP) is 1.94 Mil. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Shares Outstanding (EOP) compare to CERO and CYTOF?
Protagenic Therapeutics' Shares Outstanding (EOP) of 1.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Protagenic Therapeutics and its competitors. Protagenic Therapeutics's current Shares Outstanding (EOP) is 1.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Shares Outstanding (EOP) of 1.94 Mil. The current Shares Outstanding (EOP) is 1.94 Mil. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Shares Outstanding (EOP) is 1.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score
Get the complete analysis for PTIX
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTIX has been successfully added to your 
